Scientific Abstracts (KP) can improve health-related quality of life. In the Netherlands, the incidence of KPs and KP revisions has increased, but health care costs related to these procedures over time and their determinants are unknown.
Background: While practical guidelines and recommendations play an important role in the treatment of RA, rheumatologists often tend to deviate from these guidelines (1). This may result in disparity of quality of care among individual doctors and hospitals. To establish the best possible care, quality measures are needed. These aim to quantify the quality of the delivered care and will form the foundation of quality registries. Standardization of care processes in combination with public reporting of performance (by means of a quality registry) has been suggested to improve quality of care (2). Objectives: To develop feasible quality indicators (QIs), endorsed by the different stakeholders of the Dutch Quality registry Rheumatoid Arthritis (DQRA). Methods: An expert group of 8 rheumatologists, 2 patient representatives and 1 healthcare insurer representative developed a minimal set of QIs via a Delphi-like procedure (3), endorsed by the Dutch Society for Rheumatology. Since October 2015, these QIs have been registered by rheumatologists and rheumatology nurses, once a year in 26 hospitals, along with a patient evaluation questionnaire regarding the received care. To determine whether it is feasible to collect these QIs in daily practice, retrospective data from three hospitals was obtained (hospital A (university), B and C (non-academic)). Feasibility was determined by evaluation of: 1. Completeness of registered data (figure 1) 2. Possibility to calculate disease activity categories (remission, low-high disease activity) 3. Possibility to calculate changes over time in disease activity categories 4. Extraction of data regarding (b)DMARD use Results: Selected QIs are: 1. Percentage of patients in a certain disease activity category 2. Percentage of patients using a certain (b)DMARD 3. Patient reported experience with received care Hospital B provided only data from one year (2014) and was not able to extract data on medication from their electronic record system. 
Conclusions:
The DQRA is the first to incorporate perspectives from three stakeholders (patients, physicians and healthcare insurers) and successfully formed a limited set of QI. Collection of these indicators was feasible in two out of the three participating hospitals and offers insight in differences in provided and perceived care for RA patients. Background: Biotherapies such as subcutaneous tumour necrosis factor-alpha inhibitors (SC-TNFis) have transformed the management of rheumatoid diseases. The assessment of SC-TNFis non-persistence and its impact on medical resource utilization and costs are needed. Objectives: The objective was to assess the impact of non-persistence to subcutaneous TNF-alpha inhibitors on medical resource utilization and costs, for patients initiating treatment with an SC-TNFi in France. Methods: The Système National d'Information Inter-régime [French national health insurance scheme information-sharing system] (SNIIRAM) database lists all outpatient and inpatient healthcare consumption for individuals covered by the general health insurance scheme. Using French claims data, conditions were diagnosed using Long Term Disease status and hospital admission, based on ICD-10 codes of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Patients were then identified through first-line prescription filled for adalimumab (ADA), etanercept (ETA), certolizumab pegol (CZP) and golimumab (GLM) between 2012/07/01 and 2012/12/31. 12-months persistence status was
